Company Filing History:
Years Active: 2006-2008
Title: Innovations by Karl Nocka in Neurological Research
Introduction
Karl Nocka is an accomplished inventor based in Cambridge, MA, known for his significant contributions to the field of neurological research. He holds two patents that focus on the characterization and modulation of synaptic vesicle protein 2 (SV2) and its interactions with levetiracetam, a medication used to treat seizures.
Latest Patents
Nocka's latest patents include methods for identifying agents that bind to a levetiracetam binding site (LBS) or compete with levetiracetam binding to a LBS of SV2 proteins. These inventions provide innovative methods for characterizing the properties and functions of SV2 proteins. They also include techniques for identifying compounds that modulate the activity of SV2 proteins, particularly in relation to levetiracetam binding. Additionally, his patents offer biotinylated ligands as tools for screening chemical libraries and characterizing SV2 proteins. Another patent focuses on identifying agents for the treatment of seizures, neurological diseases, endocrinopathies, and hormonal diseases, further emphasizing the importance of SV2 proteins in medical research.
Career Highlights
Karl Nocka is associated with UCB S.A., a global biopharmaceutical company that specializes in the development of innovative medicines. His work at UCB has allowed him to explore the intricate mechanisms of neurological disorders and contribute to the advancement of therapeutic options.
Collaborations
Nocka has collaborated with notable colleagues, including Berkley Lynch and Bruno Fuks, to enhance the research and development of his innovative methods and patents.
Conclusion
Karl Nocka's contributions to the field of neurological research through his patents and collaborations highlight his commitment to advancing medical science. His work continues to pave the way for new treatments and a deeper understanding of neurological conditions.